Myopathies without EOM Weakness: Facioscapulohumeral + Myotonic Dystrophy

Home, Search, Index, Links, Pathology, Molecules, Syndromes,
Muscle, NMJ, Nerve, Spinal, Ataxia, Antibody & Biopsy, Patient Info

MYOPATHIES & NEURONOPATHIES
WITH NO EOM WEAKNESS ± FACE & PERIOCULAR INVOLVEMENT

Myotonic Dystrophy
Facioscapulohumeral dystrophy
Scapuloperoneal syndromes
Other myopathies

FSH dystrophy: Asymmetric triangular shoulders

MYOTONIC DYSTROPHY

Genetic loci
Differential diagnosis: DM1 vs DM2

Myotonic dystrophy 1 (DM 1)
Clinical features
Disease mechanisms
Epidemiology
Genetic testing
Laboratory features
Myotonin protein kinase (DMPK)
Gene
Protein
Pathology

DM 2 (PROMM)
Pathology

Also see: Gene Reviews

Myotonic dystrophy
Weakness
Face & Sternomastoids
Batten & Gibb
Brain 1909;32:187-205

Rossolimo "De la myotonie atrophique" 1902

Distal arm wasting; Wrist drop

Myotonic Dystrophy: General

2 Genetic loci
- DM 1 : 98% of families
  ● Myotonin protein kinase (DMPK) ; Chromosome 19q13.32; Dominant
- DM 2 (PROMM)
  ● Zinc finger protein 9 (ZNF9) ; Chromosome 3q21.3; Dominant
DM1 & DM2 expansions: May have originated from few founder mutations

Myotonic Dystrophy 1 (DM1)

● Myotonin protein kinase (DMPK)

; Chromosome 19q13.32; Dominant

Clinical features
Comparison to DM2
Congenital
General
Onset
Myotonia
Neural
Prognosis
Systemic
Weakness
Disease mechanisms
Epidemiology
Genetic testing
Laboratory features
Muscle pathology
Myotonin protein kinase (DMPK)
Genetic & Molecular
CTG repeats
Disease mechanisms
Generation effects: Anticipation
Protein

Also see: Gene Reviews

DM1 Gene Locus

From: Neil Miller, Johns Hopkins
Christmas Tree Cataracts

DM1: Epidemiology
- Most prevalent inherited neuromuscular disease in adults
- Prevalence in West: 13.5 per 100,000 live births
- Disease distribution: ? Associated with founder mutation arising after migration out of Africa
  - Especially common in Saguenay region of Quebec, Canada: 1:500
  - Western Europe: 4/100,000
  - Japan: 5/100,000
  - Southeast Asia: Less common
  - South & Central (sub-Saharan) Africans: Rare or absent
- Male: Female = 1:1
- Penetrance: Variable; Nearly 100% by age 50 years
- Longer CTG repeats: Earlier onset & More severe disease
- Original description by: Steinert; Batten & Gibb

DM 1: DMPK Genetic & molecular features

CTG repeats
Disease mechanisms
Generation effects: Anticipation

CTG repeats: Different numbers of copies
- Location of CTG repeat sequence in DMPK gene
  - Terminal (15th) exon of DMPK gene
  - Downstream from translation termination codon: In 3' untranslated region
- Normal ranges of CTG repeat numbers
  - Overall pattern
    - 3 to 37 CTG repeat copies (CTG_4-37)
    - Trimodal distribution
    - Alu repeat insertions (polymorphism) in CTG repeats: Associated with CTG repeat size
      - Alu repeat insertions present (Alu+): CTG₅, CTG_16-30 & expanded CTG alleles
      - Alu repeat insertions absent (Alu-): CTG_11-13
  - Low-normal number: 5 CTG repeats
    - Most common single allele in many regions
      - African Biaka & Bantu speaking; Middle East; Europe; Southeast Asia
    - Low frequency (1% - 8%) regions
      - Amerindians (Siberian Yakut; Cheyenne; Jemez Pueblo; Maya)
    - Absent in: New Guinea Highlanders; Brazil (Rondonia Surui, Ticuna, Karitiana)
  - Midsize-normal number: 9 - 17 CTG repeats
    - Most frequent (46% to 100%) range in all populations
    - Most common sizes: 11-13 repeats (15% of alleles each)
  - High-normal number: 18 to 35 repeats
    - Present mainly in Ethiopian Jews & non-Africans
    - High frequency (9% to 18%) regions
      - Ethiopian + Yemenite Jews; Japan; Danes; Yakut;
        New Guinea Highlanders; Nasioi Melanesia
    - Largest sizes (32 & 35 repeats): Ethiopian + Yemenite Jews
    - Alleles with > 19 (CTG) repeats
      - Have significant instability
      - Possible predisposing alleles for DM1 disease mutations
- Intermediate range of CTG repeat numbers: 36 to 50
  - "Premutation" alleles
  - May expand into disease range (> 50 repeats)
- Disease range of CTG repeat numbers: 50 to 4,000
  - "Protomutation" range: 50–80 repeats
    - Very mild disease: May be cataracts only
    - Transmission is mostly stable
  - Mildly affected or unaffected: 50 to 150 repeats
  - Classic disease range: 100 to 1,000 repeats
  - Severely affected range: Often congenital presentation
    - Up to 4,000 repeats
    - Hypermethylation of DMPK gene proximal to the expanded CTG repeat
  - Homozygous vs. heterozygous genotype: No clinical difference
  - Somatic (mitotic) variation in repeat size
    - More likely with repeat size > 55
    - High Initial CTG repeat size leads to
      - Progression of CTG repeat size heterogeneity over time
    - No relation to tissue proliferation capacity
  - Ancestral mutation(s)
    - Single mutation responsible for disease in patients from different ethnic origins
    - Total linkage disequilibrium DMPK mutation & nearby polymorphisms
    - Mutation arose on a predisposing haplotype(s)
    - Mid-size (CTG) repeat allele was most ancient chromosome
  - Congenital DM1
    - Aberrant methylation of Dinucleotide CpGs in region of the CTG repeat at DM1 locus
    - Increased levels of DMPK transcripts: Adult form has decreased transcripts
    - Mutation transmitted only from mother: ? Maternal imprinting
- See: Other disease expansions in transcribed but untranslated DNA

Genetic disease mechanisms in DM1

All mutations in 19q-linked DM1 have expanded CTG repeat
? Multigene syndrome + toxicity of transcribed CUG RNA repeat

3 postulated disease mechanisms

Myotonic dystrophy: Molecules & Signs
Molecule change	Related features	Disease Mechanism
DMPK reduction	Muscle weakness Cardiac conduction Δ Na⁺ channel defects	Reduced Protein from mutated gene
SIX5 reduction	Cataracts	Reduced Protein from neighboring gene
RNA with longer CUG repeats	Myotonia Diabetes Cl^- channel defects	Long CUG repeat RNA Retained in nucleus Disrupts splicing of ClC-1 pre-mRNA

DMPK (Myotonin) gene effects
- DMPK gene: Hypermethylated in congenital DM1
- DMPK protein tissue specificity
  - Heart & Skeletal muscle: Epecially 80 kDa form of DMPK
- Reduced DMPK protein levels in mice produce
  - Muscle weakness: Excitation-contraction coupling disorder
  - Cardiac conduction disorder
  - Na⁺ channel abnormalities
    - Channel number reduction lowers Na⁺ current amplitude
    - Channel gating changes: More Na⁺ channel reopenings cause inactivation
    - Repetitive activation of muscle fibers
    - Channel lesions more prominent with increasisng age after single stimulus
- Myotonic dystrophy phenotype in other tissues
  - ? Not related to abnormal DMPK protein production
CTG repeats modify production or function of other proteins coded for by neighboring genes
- Mechanisms: Enlarged CTG repeat effects on neighboring genes
  - Chromatin condensation & Hypermethylation
  - ? Chromatin disruption or Excessively stable nucleosomal region
    - Produces dysfunction of several transcription units
    - Adjacent gene expression changed: Inhibition, or Alternate splicing
- Neighboring genes of DMPK with reduced expression in DM
  - DM locus-associated homeodomain protein (DMAHP)(SIX5)
    - Myotonic dystrophy CTG repeat near, & 5' of, enhancer element for SIX5
    - SIX5 sequence homology
      - Homeodomain-encoding genes
      - To gene involved in development of muscle in lower legs (mouse)
    - ? SIX5 may regulate transcription from Na⁺/K⁺-ATPase α-1 subunit (ATP1A1) promoter
    - Activator that directs Igfbp5 expression
    - SIX5 disease: Branchio-Oto-Renal Syndrome
    - SIX5 deficiency in mice
      - Produces ocular cataracts
      - ? Increased ATP1A1 activity
      - Heterozygosity: Cardiac conduction abnormalities
      - Normal skeletal muscle
  - DMWD
    - Contains WD repeat
    - WD repeat is found in some proteins that regulate development
    - DMWD mRNA levels in DM1 skeletal muscle are normal
Elongated CTG repeat DNA produces RNA with excessive numbers of CUG repeats: Dominant negative effect
- Mutant, elongated (CUG)_n DMPK transcripts accumulate
  - Develop stable secondary structure in vitro
    - C-G & G-C base pairs separated by U-U mismatch
  - Accumulate in nuclei
- Proteins or DNA bind to (CUG)_n repeat RNA
  - RNA binding proteins: General
    - Regulate alternative splicing of specific pre-mRNAs by binding to U/G–rich motifs
  - Candidate proteins binding to (CUG)_n repeat RNA
    - (CUG)_n triplet repeat expansion (EXP) ds-RNA binding (Muscleblind) proteins ⁴
      - Muscleblind-like protein (MBNL)
      - MBLL
      - MBXL
  - Features of protein binding to repeat RNA
    - Proteins bind to expanded CUG hairpins
    - Binding is stronger than to CAG repeats or non expanded CUG repeats
    - May produce: Sequestration or dysfunction of muscleblind proteins
      - Muscleblind proteins localized with expanded CUG repeats in nuclear foci
      - Muscleblind proteins reduced in other regions of nucleoplasm
      - Changes associated with abnormal regulation of alternative splicing of pre-mRNAs
      - Aggregates present in neuronal nuclei: May be associated with CNS signs in DM1
  - Cell localization of muscleblind proteins in myotonic dystrophies
    - Along with expanded CUG or CCUG repeat RNA
    - Location: Nuclei of DM1 & DM2 cells
- Functional effects of long CUG repeat RNA: Varies in different tissues & with repeat length
  - Muscle: Aberrantly spliced RNA action produces altered proteins
    - CLC1 (chloride) channel
      - Abnormal channel proteins have no Cl^- conductance
      - Interfere with function of normally spliced Cl^- channels
      - Altered splicing variants: Two common types
        
        Inclusion of novel exons 6b and 7a: Causes a frameshift & premature truncation at codon 283
        
        Skips exon 6 & includes exons 6b and 7a: Results in premature truncation at codon 257
      - Reduced overall Cl^- channel function: Produces myotonia
      - Abnormal splicing effect is expressed as mosaic
        
        Some muscle fibers with more reduction of Cl^- channel than others
    - Ca_v1.1 (Calcium channel, L-type) ³⁶
      - Alternative (misregulated) splicing of exon 29: Reduced from presence in 93% of protein to < 30%
      - Associated with 2 splicing factors: MBNL1 & CUGBP1
      - May modify Ca_v1.1 channel function: Increased conductance & voltage sensitivity
      - Severity of weakness: Correlates with degree of alternative splicing
      - May also play a role in DM2
      - Mouse model: Increases frequency of central nuclei in muscle fibers
  - Brain: Aberrantly spliced RNA produces altered splicing of several proteins
    - NMDA receptor 1 (NMDAR1): 3-fold increase in fraction of mRNA that includes exon 5
      - Altered pharmacology, gating & cellular distribution (somatic rather than somato-dendritic expression)
    - Microtubule-associated protein tau (MAPT): Increased fetal isoforms (Absent exon 10)
    - APP protein: Fetal splice isoforms (Exon 7 exclusion products)
  - Other abnormal splicing
    - Insulin receptor: Insulin resistance
    - MTM1
    - SERCA
  - Longer CUG repeat RNA
    - Produces more abnormal splicing of Cl^- channel
    - More myotonia
  - DM2 (PROMM): Similar pathological splicing effect of elongated CCUG repeat sequence
- Mouse models: Insertion of long CTG repeat in muscle ²
  - Expresses long untranslated (CUG)_n RNA repeat
  - Effects of long CUG repeat RNA: Abnormal splicing of other muscle RNA
    - CLC1 (chloride) channel
      - Altered splicing adds exon 7a to RNA
      - Aberrantly spliced RNA produces altered Cl^- channel protein with reduced function
      - Reduced Cl^- channel function produces myotonia
    - Insulin receptor
      - Altered splicing reduces number of insulin receptors
      - Associated with diabetes
  - Clinical: Myotonia beginning at 4 weeks of age; No clear weakness
  - Electrophysiology: Myotonia
  - Microphysiology: Markedly reduced Cl^- channel conductance
  - Pathology: Myopathy
    - Central nuclei
    - Varied fiber size, ring fibers
    - High SDH & COX activities
    - No muscle wasting or weakness
- Brain CTG repeat expansion: Autosomal dominant cerebellar degeneration (SCA8)

Generation effects on mutations & disease: Increased Severity with progressive generations
- CTG repeat # in normal range: Population genetics
  - Mutations in small CTG repeats probably occur in small increments or decrements
  - (CTG)₅ allele probably arose from mutation of (CTG)_9-17 allele on Alu+ chromosome
- Possible origin of large CTG repeat #: Many DM mutations descend from a few founder chromosomes
  - Mutation from: (CTG)_18-35 on a Alu+ chromosome
  - Alu+ chromosome
    - May predispose (CTG)_18-35 expansion (mutation) to pathological range
  - Founder mutation populations
    - Ancestral to non-Africans in Africa: Prior to population divergence
    - Occasional other families
  - Mutation to (CTG)_50-80 allele with higher frequency than shorter CTG repeat #'s
- Features of CTG size variability
  - Repeats & disease severity often increase in successive generations
    - 50 to 80 repeats often show intergenerational stability in number
    - Repeats with > 80 elements especially prone to large amplifications
    - Repeat contractions are reported
  - CTG expansions < 100 more unstable in sperm than egg
    - Change from minimal to classical DM1 usually transmitted through male germline
  - Intergenerational variation
    - Increases in expansion sizes occur during gametogenesis but not during meiosis
    - Repeats increase most with maternal transmission
      - Increases in number of repeats: In embryos from DM1 females & in their immature and mature oocytes
      - Bias against very large expansions in sperm
      - Maternal transmission mostly responsible for congenital myotonic dystrophy
  - Somatic variation in CTG repeat length also occurs
    - More likely with repeat size > 55
    - High Initial CTG repeat size leads to
      - Progression of CTG repeat size heterogeneity over time
    - Repeat sizes may increase ~50–80 repeats per year
    - Tissue variability: Repeat expansion sizes
      - Smallest in blood
      - Largest in heart, muscle, and kidney
    - Marked somatic mosaicism
      - Becomes apparent from the 2nd trimester of development onward
      - Increases during adult life
    - Repeat lengths in muscle are very large
      - 2x to 13x greater in muscle than in peripheral blood cells
      - No correlation between size of repeats in muscle and degree of weakness
    - Somatic instability probably more related to DNA repair mechanisms than to mitosis
      - 1st & 2nd trimester fetuses have homogeneous distribution of repeat lengths in different tissues
      - Enlargement of expanded repeats can occur throughout life: Even in post mitotic cells
  - Instability of expanded CTG repeats varies among species
    - Transgenic CTG repeat sequences in mice are relatively stable

DM1: Myotonin protein kinase (DMPK) protein
- 68 to 80 kDa protein
  - 6 Splice variants
  - Splice variant sub-types localized in different tissues
- Action
  - Sub-family: Rho-kinases
  - Serine/Threonine protein kinase
  - Possible cell functions
    - Cell shape determination
    - Regulation of actin-myosin contractility
    - Modulation of activity of voltage-gated ion channels
    - Nuclear envelope stability ³⁸
  - Loss of DMPK
    - Abnormalities of Ca⁺⁺ homeostasis
    - Altered excitation-contraction coupling
    - Homozygous knockout mice: Cardiac conduction defects
- Structure: PK catalytic domain - Coiled coil domain - Hydrophobic domain
- Cell localization
  - Near sites of dense channel clustering
  - Major proportion is cytosolic
  - Muscle DMPK: NMJ; Terminal cisternae of sarcoplasmic reticulum; I-band
  - Heart: Intercalated discs (focal adhesions)
- Tissue localization
  - Present in all tissues
  - Heart & Skeletal muscle: 80 kDa form especially prominent; Highest levels
  - Non-muscle tissues: 72 kDa form predominates
- DMPK in Myotonic dystrophy
  - Nuclear retention of DMPK transcripts with expanded CUG repeats
  - Reduced DMPK poly(A)⁺ mRNA in DM fibroblasts & muscle biopsies
  - DMPK protein levels in muscle
    - Adult myotonic dystrophy: Mild decrease or increase
    - Congenital myotonic dystrophy: Minor reduction
    - Myotonic dystrophy myoblasts: Normal
DM1: Clinical features

Congenital
General
Onset
Myotonia
Neural
Prognosis
Systemic
Weakness

Rossolimo "De la myotonie atrophique" 1902
- General
  - Marked variation in severity within families
  - Anticipation
    - Mean symptom onset 29 years earlier in child compared to parent
    - Due to tendency of GTG repeat to enlarge when transmited from 1 generation to next
  - Strong relationship of clinical syndromes to age of patient and age of onset
- Onset: Neonatal to Late adulthood
  - Age of onset: General
    - Correlates with length of repeat when CTG # is les than ~ 400
  - Neonatal: CTG repeat length 1,000 to 4,000
  - Childhood: CTG repeat length 50 to 1,000
    - Onset age: 1 to 10 years
    - Mental retardation
    - Motor: Delay; Face weakness
    - Myotonia
    - Cardiac: Conduction defects
  - Adult: CTG repeat length 50 to 1,000
    - Onset age: Especially 2nd to 4th decade
    - Weakness: Finger flexors; Neck flexors; Face; Respiratory
    - Myotonia: Grip
    - Cataracts
    - Insulin resistance
    - Cardiac: Conduction defects
  - Older adult (Minimal or Asymptomatic DM1): CTG repeat length 50 to 100
    - Onset age: 20 to 70 years
    - Myotonia: Mild
    - Cataracts
  - Pre-mutation: CTG repeat length 38 to 49
    - No clinical features
    Myotonic dystrophy
    Distal leg wasting
- Weakness
  - Cranial
    - Face: Superficial muscles; Eye & mouth closure; Temporalis
    - Ptosis (Symmetric; Partial): Levator palpebrae superioris
    - Masseter
    - Palate ± Tongue: Indistinct speech
    - No ophthalmoplegia
  - Neck: Flexors & Sternomastoids
  - Proximal
    - Quadriceps; Diaphragm & Intercostals
    - Affected later in disease
  - Distal
    - Wrist & Finger extensors
    - Grip
    - Ankle > Toe dorsiflexors
  - Muscles frequently spared: Pelvic girdle; Hamstrings; Soleus & gastrocnemius
  - Late in disease course: Diffuse weakness
  - Wasting: Common; Early in volar forearm
- Myotonia
  - Evoked by percussion or muscle contraction
  - Onset: 5 to 25 years; Not congenital
  - Severity
    - Rarely causes disability
    - Milder than myotonia congenita
    - Correlates with leukocyte CTG repeat length¹⁵
  - Treatment: Little functional benefit
  - Cause: Reduced chloride (CLC-1) channels in sarcolemma
- Muscle pain: Occasional patient
- Neural
  - CNS
    - Personality: Avoidant; Apathy
    - Hypersomnia
      - Excessive daytime sleepiness
      - ? Related to loss of serotonin (5-HT) neurons
        
        Dorsal raphe & Superior central nucleus of brainstem
      - Treatment
        
        ? Modafinil 200 to 400 mg/day⁵
        
        Avoid arrhythmogenic drugs
    - Mental retardation (10% to 24%): Congenital; Non-progressive
    - MRI: Subcortical white matter changes
    - Brain pathology
      - Neurofibrillary tangles with 3- & 4-repeat tau ⁵¹
      - Ribonuclear foci: Contain transcripts including muscleblind-like splicing regulator 1 (MBNL1)
  - PNS: Sensory neuropathy, Mild (Rarely functionally significant)
- Systemic
  - Face
    - Frontal balding
    - Temporal wasting
    - Ptosis
    - Hatchet face
  - Eyes
    - Cataracts
      - Features: Posterior subcapsular; Multiple; Punctate
      - Detection: Slit lamp needed
    - Ptosis
    - Retinal degeneration
    - Ciliary body weakness (Low intraocular tension)
  - Endocrine
    - Hypogonadism
      - Testicular atrophy
      - 1° Tubular degeneration
      - Testosterone: Reduced
      - Oligospermia
    - Pituitary
      - Follicle Stimulating Hormone (FSH) may be increased
      - Growth hormone: Reduced release
    - Insulin resistance
    - Pregnancy: Frequent fetal loss & major complications
    - Insulin-like growth factor-1 (IGF-1): Reduced
    - Hypertriglyceridemia (67%)
  - Respiratory
    - Reduced response to hypoxia; Hypercapnia
    - Hypoventilation: Pickwickian syndrome
    - Aspiration pneumonia: 2° esophageal dysfunction
    - Sleep disorders ³⁷
      - Obstructive sleep apnea (55%)
      - Periodic breathing
      - Sleep hypoventilation
  - Cardiac
    - General
      - Increased frequency & severity with: Increased age; Greater # CTG repeats
      - Occasional involvement in patients < 18 years
        
        Childhood or Congenital DM1: Ventricular arrhythmias
        
        Initial events in previously asymptomatic DM1 teenagers
        
        Cardiac arrest
        
        Atrial arrhythmias
    - Conduction & Rhythm defects
      - Ectopic beats
      - Tachyarrhythmias
      - Atrial fibrillation, flutter & tachycardia
      - Conduction disease: His-Purkinje system
      - Sudden death
    - ± Cardiomyopathy: Especially late in course
    - Indications for cardiac evaluation & treatment ³⁹: Screen with yearly EKG
      - PR interval > 200 ms
      - QRS duration > 100 ms
    - N-terminal pro B-type natriuretic peptide: May be high with cardiomyopathy
    - Treatments
      - Ablation of His-Purkinje branch
      - Pacemaker or Defibrillator
  - Gastrointestinal
    - Dysphagia (Pharyngeal or Esophageal)
    - Hypokinesis: Megacolon; Constipation; Pseudo-obstruction
    - Cholelithiasis
  - Skeletal
    - Small sella turcica
    - Frontal bossing
    - High arched palate
    - Air sinus size: Increased
  - Smooth muscle: Esophagus; Colon (Constipation); Anal Sphincter; Uterus; Gall bladder
  - Skin
    - Calcifying epithelioma
    - Pilomatricoma (Pilomatrixoma)
    - Frontal balding
  - Neoplasms
    - Pilomatricomas, Multiple
    - Increased risk ⁴³
      - Reproductive
        
        Testicular (10.7x)
        
        Endometrial (7.0x)
        
        Ovary
      - Non-Hodgkins lymphoma (4.3x)
      - Skin
        
        Basal cell: Younger onset age
        
        Non-melanoma
      - Endocrine: Thyroid & Non-thyroid
      - Brain tumors: Pediatric & Adult
- Medications to avoid
  - Amitriptyline, Digoxin, Procainamide, Propranolol, Quinine, Sedatives
  - Medication being studied: Metformin (3g/day) ⁴⁵
- Prognosis with adult onset
  - Reduced survival to age 65: Mean age at death 60 years
  - Minor correlation between CTG repeat length & younger age at death
  - 50% of patients wheelchair bound shortly before death
  - Causes of death
    - Pneumonia & Respiratory insufficiency (> 30%)
    - Cardiac arrhythmia (Sudden death) (30%): Heart block; Ventricular tacharrhythmia
DM1: Congenital onset & Mental retardation

from A Kornberg
Congenital myotonic dystrophy
- Epidemiology & Occurrence
  - Frequency
    - 10% to 15% of DM1
    - 25% of offspring of myotonic mothers
    - Very rarely from fathers
  - Obstetric problems
    - Inversely correlated with age at onset of maternal DM
  - No effects on gestational outcome
    - Age at delivery
    - Birth order
- Genetics: CTG repeats
  - 730 to 4,300 repeats
  - Hypermethylation of mutated allele
- Clinical
  - Onset: Prenatal
  - Pregnancy
    - Polyhydramnios
    - Decreased fetal movements
    - Breech presentation
    - Prematurity: Pre-term labor
  - Motor
    - Hypotonia
    - Failure to thrive: Due to an inability to suck
      - Caused by: Bilateral facial & jaw muscle weakness
      - Facial appearance: Mouth open; Tented upper lip; High-arched palate
    - Neonatal respiratory distress (50%)
      - Patient may eventually be weaned from respirator
    - Delayed motor milestones
      - Parallels degree of hypotonia
      - Delayed speech
      - Slow improvement
      - Most patients eventually walk independently
  - Muscle: No myotonia
  - Tendon reflexes: Absent
  - CNS: Mental retardation
    - IQ levels: 40 to 80 in 50%–90% of patients
    - No progression
    - Behavioral abnormalities: Hyperactivity attention deficit; Autistic behavior
    - Most able to care for themselves
    - Neuroimaging: Ventricular dilatation from birth (50%)
  - Skeletal
    - Craniofacial: Tapered chin, High-arched palate, Prominent brow
    - Arthrogryposis
- Laboratory
  - EMG: No myotonia
  - CK: Usually normal
  - Muscle biopsy ³⁴
    - Histochemistry
      - Normal or Non-specific
      - Internal nuclei: Some patients
    - MBNL1 nuclear staining
      - CDM: Foci, discrete
      - Controls: Diffuse & Hetergeneous
  - MRI
    - Enlarged ventricles
    - Some with hypoplasia of corpus callosum & Cerebral white matter change
    - Cerebral atrophy: Global
- Diagnostic (prenatal) tests
  - Amniocytes & villi may not accurately represent CTG repeats in fetal blood
  - Evaluate mother & pregnancy
  - Measure CTG triplet repeat in mother & fetus
  - High risk: 300 repeats in villi; 600 repeats in mother; Polyhydramnnios

DM1: Differential diagnosis vs DM2 (PROMM)

DM 1 vs DM 2 Comparative features
Feature	DM 1	DM 2
GENERAL
Epidemiology	Widespread	European
Onset Age	0 to Adult	8 to 60 years
Anticipation	+	Rare
Congenital form	+	No
Life expectancy	Reduced	Normal
MUSCLE
Weakness Face Ptosis Sternomastoid Proximal legs Distal Bulbar	+ + + Late + +	Mild Mild Variable Early FDP -
Muscle pain	±	++
Myotonia	+ Adult	+ Variable
Muscle size	Atrophy Face Distal limbs	Hypertrophy Calf
SYSTEMIC
Cataracts	+	Some
Balding	+	Rare
Cardiac arrhythmias	+	Variable
Gonadal failure	+	20%
Hypersomnia	+	Variable
Hyperhidrosis	Variable	+
Cognitive disorder	Mild to Severe	Mild
LABORATORY
Hyperglycemia	+	20%
EMG: Myotonia	+	+
Muscle Internal nuclei	Distal muscle	Type 2 fibers
Chromosome	19q13.3	3q21
Mutated gene	DMPK	ZNF9
Mutation type	CTG repeats	CCTG repeats
Repeat size	100 to 4,000	Mean ~5,000
CNS MRI Δ	White & Gray matter	White matter

DM 1: Laboratory features
- Serum
  - CK: Normal to 3x
  - Endocrine
    - Testosterone: Low
    - FSH: High
    - Insulin insensitivity
  - IgG: Low
  - Neurofilament light chain: High; Correlates with onset age & disease severity ⁵³
  - Phosphorylated Tau: High
- Muscle MRI: Muscles prominently & consistently involved¹⁹
  - Medial heads of gastrocnemius
  - Soleus
  - Vastus medialis
- EMG
  - Myotonia
    - Onset
      - After 1st decade
      - Not present early in congenital Myotonic dystrophy
    - Distribution
      - Face
      - Distal > Proximal
    - Duration
      - Myotonic runs longer on average than myotonia congenita
      - Many > 2 sec & longest 30 sec
    - Pattern: Waxing & Waning
    - Severity
      - Correlates with degree of weakness
      - More with waxing & waning
  - Myopathic potentials: Distal > Proximal
- Genetic testing: Indications ¹
  - Diagnosis in symptomatic patient: Confirm typical, or uncertain atypical, syndrome
  - Asymptomatic patient: Determine progenitor for genetic counseling & a priori risks of inheriting
  - Minors: Should generally not be tested unless symptomatic & diagnosis necessary
  - Prenatal testing: Assess fetal risk in diagnosed parent
  - Confidentiality & DNA property rights should be addressed in informed consent
- Muscle biopsy
  - Myopathic changes
    - Varied fiber size
    - Endomysial connective tissue: Mildly increased; Late
    - Occasional myopathic changes
      - Type I fiber smallness: Especially in deltoid or biceps; Early in disease process
      - Type I fiber predominance: Severely affected muscles
      - Ring fibers
      - Sarcoplasmic masses
  - Myonuclei
    - Internal nuclei: Numerous; Varied depths within muscle fiber
    - Increased number
    - Pyknotic nuclear clumps
    - Intranuclear RNA inclusions: Foci of CUG repeats
    - Muscleblind-like 1 (MNBL1) nuclear foci
  - Muscle spindles: Intrafusil muscle fibers
    - Increased number
    - Reduced size
    - Abnormal fiber tyes: More type 1
  - Ultrastructure
    - Myonuclei: Irregular contours
    - Sarcoplasmic reticulum: Dilated terminal cisternae
    - Sarcoplasmic masses
  - Congenital DM1
    - Small muscle fibers
    - Occasional internal nuclei
    - Fiber type differentiation: Poor
    - Nuclear foci with muscleblind-like 1 (MBNL1) protein ³⁴
    - Ultrastructure: Disordered myofibrils; Clustered tubules with electron dense cores
- CNS (MRI) ³⁵
  - Gray matter
    - Reduction of frontal & parietal gray matter
    - Abnormal thalamic gray matter & hippocampus
  - White matter lesions
    - Frequency: > 50%
    - Extent correlated with: Psychomotor speed; Age; Disease duration
    - Prominent callosal body & limbic system involvement
    - Milder involvement: More depression & fatigue
  - More severe in DM1 than DM2
    - Gray matter involvement
    - Central motor pathways

Myotonic Dystrophy, Type 3 (DM3)¹⁶
● Identified as IBMPFD

FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) ⁵⁴

FSH 1A: DUX4; 4q35
Clinical features
Clinical correlations
DUX4 protein
Epidemiology
Genetics
Laboratory
FSH Variants
Infantile FSH 1A
FSHD1
Bent spine
Digenic: DUX4 +
FSHD2: SMCHD1; 18p11
FSHD3: LRIF1; 1p13
FSHD4: DNMT3B; 20q11
FSHD: D4Z4 deletion; 10qter

FSH Differential Dx
non 4q35 FSH
FSH 1B
Mitochondrial
Scapuloperoneal
VCP

External link
Gene reviews

FSH Dystrophy Triangular Shoulders Poly-Hill sign

NLM

Louis Théophile
Joseph Landouzy

NLM

Joseph Jules
Dejerine

FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1A (FSHMD 1A)

● Double homeobox protein 4 (DUX4)

(D4Z4 repeat DNA deletion); Chromosome 4q35.2; Dominant
● Double homeobox protein 4 (DUX4)

(D4Z4 repeat DNA deletion); Chromosome 10qter; Dominant

Nosology
- Landouzy-Dejerine Syndrome: External link
FSH: Epidemiology
- Frequency
  - Prevalence: 1 per 8,500 to 15,000
  - 3rd most common dystrophy after Duchenne & Myotonic
  - Large family in Utah ⁷
- Males more often symptomatic compared to Females
  - More females with gene defect are asymptomatic
  - Penetrance by age 30: 95% for Males; 69% for Females
  - Males have: Earlier onset; More common foot extensor weakness

Genetics: FSH dystrophy and 4q35 DNA

Disease mechanisms: FSH
FSHD1: DUX4
Digenic
FSHD2: SMCHD1
FSHD3: LRIF1
FSHD4: DNMT3B
FSHD 10qter
General principles
Genetics: FSH 4q35 locus
Normal
Mutations
FSH
New
No disease
Size

Charcot

Chromosome 4q35
NORMAL FSH LOCUS D4Z4 DNA repeats Number: Normals; 11 to 150 Methylation: High Chromatin: Closed Contain: Part of DUX4 gene 4qter region: Distal to repeats: 2 types 4qA type region Contains Full distal DUX4 gene Polyadenylation signal Distal D4Z4 + 4qA contain Complete DUX4 retro gene Somatic Polyadenylation Signal DUX4 not expressed 2° methylation 4qB type region Defect: No DUX4 distal exon Chromosome 10: Homologous region Defect: No polyadenylation signal		FSHD1 LOCUS D4Z4 DNA repeats Number: Reduced; 1 to 10 Methylation: Low Chromatin: Open Contain: Part of DUX4 gene Full DUX4 gene Locations: Parts in Most distal D4Z4 repeat Telomeric DNA next to distal repeat Expression: Possible with 4qA haplotype Reduced repeat methylation 4q region distal to D4Z4 repeats A haplotype: Permissive Contains full distal DUX4 gene Allows expression of stable, polyadenylated DUX4 B haplotype: Not Permissive DUX4 expression pathway Requires p38 activity

Sachs

FSH Disease locus at Chromosome 4q35 (telomere): DNA in Normals
- Tandem repeat KpnI DNA (D4Z4) units
  - Location: Subtelomeric region of chromosome 4
  - Size of repeats: 3.3 kb
  - Number of repeats
    - Usual: 11 to 100 (> 40 kB)
    - Other: Contracted D4Z4 repeats on nonpathogenic haplotypes
  - KpnI Tandem repeat units at 4q35 contain
    - 2 homeobox sequences
    - 2 different GC-rich repetitive sequences
    - Euchromatic features: Open reading frame (DUX4 gene)
      - Each unit of repeat array contains a copy of: Retrogene double homeobox 4 (DUX4)
      - DUX4: Normally expressed in testis & silenced in somatic tissue
      - Stable DUX4 expression
        
        Requires: Polymorphic polyadenylation signal (PAS)
        
        Location: Immediately distal to D4Z4 repeat array
        
        Present in 4qA chromosomal regions
        
        Does not occur with: 4qB regions or in 4q10
    - Heterochromatic features
      - Highly condensed DNA
      - Associated with: Highly methylated, hypoacetlyated histone H4
      - Little transcription
      - Contain low-copy heterochromatic repeats: hhspm3 & LSau
  - D4Z4 methylation
    - Definition: Covalent post-synthetic modification of cytosines engaged in CpG dinucleotides
    - Levels on D4Z4 repeat region
      - Linearly correlate with size of the D4Z4 array in control & FSHD individuals
      - Reduced with repeat lengths less than 11
    - FSHD: Reduced
  - Other features of repeated DNA at 4q35 in normals
    - Normal DNA size: >40 to 300 kb
    - No genes normally expressed
    - High (> 98%) homology to DNA repeats on telomere of chromosome 10qter
  - Only disease-related macrosatellite repeat
- cis elements distal to the D4Z4 repeat: Polymorphic 4q DNA segment distal to D4Z4 repeats ⁹
  Matt Harms
  - Size: 10 Kb
  - 2 or 3 Alleles: 4qA & 4qB; ? 4qC
    - 4qA
      - Contains beta-satellite & other cis elements sequences
      - Contains polyadenylation signal: May stabilize expressed DUX4
    - 4qB: Lacks beta-satellite, polyadenylation signal & other cis elements sequences
    - ? 4qC in 2% of population
    - General population
      - Chromosome 4: 4qA 42% & 4qB 58%
      - Chromosome 10: Only 4qA-like allele
  - FSH only occurs with cis 4qA161 type segment
- 4q35 telomere features
  - Closely associated with the nuclear envelope ¹⁷
    - 4q35.2 localizes to nuclear rim, an area rich in nuclear envelope proteins
    - Localization to nuclear rim: Requires lamin A/C; Not related to D4Z4 repeats
  - Most other telomeres clustered within nucleoplasm

FSH Disease Locus at 4q35 in FSHD: Features in & near D4Z4 DNA fragment ^29, ³¹

General
- D4Z4 repeat
  - Sizes
    - Intermediate: FSHD2; FSHD-DNMT3B; FSHD-LRIF1
    - Small: FSHD1
  - Methylation Reduced
    - FSHD1; FSHD2; FSHD-DNMT3B; FSHD-LRIF1
- 4qA allele: FSH disease permissive haplotypes telomeric to D4Z4 repeat
  - Contains FSHD-predisposing single nucleotide polymorphisms (SNPs)
  - Creates canonical polyadenylation signal for transcripts derived from DUX4
  - Polyadenylated DUX4 transcripts: More stable
  - Stabilized, expressed distal DUX4 transcript: May produce toxic gain of function
  - FSH Pathogenic 4qA types: 4A161, 4A161L, 4A159, 4A168, 4A166H
  - Non-pathogenic 4qB types: 4B163, 4B168, 10A166, 10A164, 10B161T & 10A176T

FSHD1
- FSH disease expression requires
  - Deletion in units of D4Z4 DNA repeat sequence
    - Remaining D4Z4 fragment
      - Size: Reduced
      - At least 1 D4Z4 unit remaining
      - Hypomethylated
    - Allows: Increased expression of DUX4 gene in distal repeat
  - Permissive sequences: Distal to D4Z4 repeats
    - 4qA allele(with β-satellite sequences) (4qA161) distal to repeats
    - Lead to: Polyadenylation, Stabilization & Translation of distal DUX4 mRNA transcript
- D4Z4 repeats in fragment with deletion
  - Contain gene for: Double homeobox protein 4 (DUX4) ⁵⁵
    - Double homeobox gene
    - Function: Unknown
    - FSHD relevant DUX4 gene
      - Straddles distal D4Z4 repeat unit & adjacent sequence
      - Encompasses two facultative introns in the 3'UTR
      - Contains pLAM sequence immediately distal to D4Z4
        
        Polymorphisms affect polyadenylation of distal DUX4 mRNA transcript
    - Non-FSH 4qA distal alleles: DUX4 transcript not adenylated; Short half-life
    - FSH 4qA alleles: Polyadenylated DUX4 transcript; Stabilized
  - Hypomethylated D4Z4 repeat
    - Selective for D4Z4 repeat
    - May allow increased expression of DUX4 transcript
    - Causes: Open chromatin structure
    - May affect DUX4 transcriptional activity (with associated 4qA161 haplotype)
  - D4Z4 chromatin structure: Open
  - Reduced numbers of D4Z4 repeats
    - ≤ 7 repeats: Most common FSHD mutation
    - 8 to 11 repeats
      - Reduced disease penetrance
      - May be digenic disease with: SMCHD1; DNMT3B
- 4qA allele
- FSHD1: Disease modifiers & Digenic FSHD
  - SMCHD1
    - Methylation of D4Z4 ≤ 22% of expected: Often have SMCHD1 mutations
    - Mutations: Modify disease severity in FSHD1 with alleles of 8–10 D4Z4 units
    - Also related to methylation on
      - Inactive X chromosome
      - Imprinted genomic regions
  - LRIF1
  - DNA methyltransferase 3B (DNMT3B)
    - Responsible proper de novo cytosine methylation profile during development

Facioscapulohumeral Dystrophy 2 (FSHD2; FSHMD1B), Digenic

● Structural maintenance of chromosomes flexible hinge domain containing 1 (SMCHD1)

;
Chromosome 18p11.32; Dominant (Digenic with permissive DUX4 allele)

Epidemiology: ~50 families, Dominant & Sporadic

Genetics

SMCHD1 gene ⁴⁰

Mutations: Missense; Splice site; Deletion; 18p monosomy or deletion
Disease mechanism: Haploinsufficiency
FSH penetrance more with
- Shorter D4Z4 repeats (8 to 20)
- 4qA, Permissive, allele
- Frequency: 80%
Allelic disorder: Bosma arhinia microphthalmia syndrome
- Mutations: de novo; Missense; Heterozygous
- Location: In extended ATPase domain

D4Z4 repeat

Size
- Usually intermediate (9 to 16 repeats) ⁴⁷
- Some patients with > 20 repeats (21 to 70) ⁴⁶
  - Also have D4Z4 duplications associated with D4Z4 repeats
  - D4Z4 duplications: Followed by small FSHD-sized D4Z4 repeat arrays
Hypomethylation: D4Z4 genetic repeats
- Location: Normal (or small) D4Z4 alleles
- D4Z4-restricted: On both alleles on chromosomes 4q & 10q
D4Z4 chromatin structure: Open; Less compact than FSHD1
Genetic defect in D4Z4 methylation: May cause disease
DUX4 expression: Permissive sequences distal to D4Z4 repeats required
- Lead to: Polyadenylation & Stabilization of distal DUX4 transcript

DNA telomeric to D4Z4 repeat

At least one 4qA161 subtelomere on 4q35 required for disease expression

Some FSHD2 families: Repeat array + Heterozygous mutation in DNMT3B

FSHD2: SMCHD1 gene mutations
Locus at chromosome 4q35
D4Z4 DNA repeats
Number: Intermediate (8 to 20)
Methylation: Low
Chromatin: Open
DUX4 gene: Increased expression
4qA region distal to repeats
Permissive
Allows expression of
stable polyadenylated DUX4

SMCHD1 protein
- Binds to D4Z4
- Regulates chromatin expression
- Hypermethylation of subset of CpG islands associated with X-chromosome inactivation
- Mutation
  - D4Z4 repeat: Hypomethylation
  - DUX4 expression: Increased in muscle
Clinical: FSHD-like disease
- General: Similar features to FSHD1
- Onset age: > 30 years
- Face weakness
- Scapular Winging
- Muscle weakness
  - Proximal
  - Distal legs: Occasional¹⁰
  - Severe weakness: May have both FSHD1 & FSHD2 mutations

FSHD3, Digenic ⁴⁸
● Ligand-dependent Nuclear Receptor-Interacting factor 1 (LRIF1) ; Chromosome 1p13.3;
Recessive (Digenic with permissive DUX4 & 4qA allele)
- Epidemiology: 1 patient
- Genetics
  - Mutation: Homozygous; Frameshift; c.869_872dup in exon 2
  - D4Z4 repeat: 13 units on 4qA haplotype
  - Mutation effects
    - Loss of longer LRIF1 isoform
    - D4Z4 hypomethylation
- LRIF1 protein
  - Interacts with SMCHD1
  - Interacted with several human nuclear hormone receptors
  - Loss of LRIF1 large isoform: DUX4 derepression in myogenic cells
- Clinical: FSHD2 phenotype
  - Onset age: Adult
  - Weakness
    - Limbs: Arms & Legs
    - Face
    - Trunk: Neck
    - Asymmetry
- Laboratory
  - Serum CK: 89
  - Muscle CT: Asymmetric; Biceps brachii, Quadriceps femoris, Gastrocnemius, Paraspinal
  - Muscle pathology: Small, immature muscle fibers
FSHD4, Digenic ⁴⁴
● DNA methyltransferase 3B (DNMT3B) ; Chromosome 20q11.21;
Dominant (Digenic with permissive DUX4 & 4qA allele)
- Epidemiology: 2 families
- Genetics
  - Mutation locations: Cys527Arg; Pro691Leu
  - Mutation effect: Reduced D4Z4 methylation
  - Digenic: FSHD with 9 to 13 D4Z4 repeats & DNMT3B mutation
  - Allelic disorder: Immunodeficiency, Centromeric instability & Face anomalies (ICF1
- DNMT3B protein
  - Known D4Z4-chromatin modifier
- Clinical: FSHD

FSH Disease locus at Chromosome 10qter telomere in FSHD
- Epidemiology: 1 patient identified
- D4Z4 repeat: Mosaic pathogenic
  - Start D4Z4 unit: Chromosome 10-type, 2 1/2 repeats
  - Distal end of D4Z4 unit: Chromosome 4-type, 1 1/2 repeats
- Terminal 4qA locus: Contains directly adjacent polyadenylation-promoting pLAM sequence
- No FSHD candidate genes located proximal to D4Z4 repeat
FSH and 4q35 DNA: 2 Disease-related polymorphisms
- Deletion in subtelomeric repeat sequence: Reduced numbers of D4Z4 DNA (KpnI) repeats
  - Normal D4Z4 repeat features
    - Size of single repeat element: 3.3 kb
    - Normal numbers of repeat elements: 11 to 150
  - FSH D4Z4 repeat features
    - FSH repeat number: 1 to 10 D4Z4 tandem repeats; 10 to 34 kb
    - Pathogenic feature: Number of KpnI DNA repeats is reduced to less than 11 but more than 0
  - Deletions in chromosome 10q DNA when on 4q35: ? Also related to FSH disease
- cis elements distal to D4Z4 repeat: Only 4qA polymorphism is associated with FSH disease
- FSH 4q35 genetic characteristics
  - Disease only occurs with: Both D4Z4 contraction and 4qA allele on same chromosome
  - FSHD alleles (deleted D4Z4, presence of beta-satellite)
    - Marked hypomethylation of D4Z4 repeat unit relative to normal alleles
- Mutation present but not detected by routine testing ²²
  - Large proximal deletion that includes usual p13E-11 DNA probe site
  - Occasional FSH patients with no deletion have hypomethylation of 4q D4Z4 repeat block
FSH: New mutations
- Related to
  
  10qter LOCUS in most normals
  D4Z4 repeat units with
  Homology to units at 4q35
  No 4qA distal to repeat units
  No polyadenylation signal
  - Somatic mutations: 40% of new mutations
  - Homologous DNA configuration to Chromosome 4q35 FSH locus
    - Location: Chromosome 10qter
    - Translocations between 4q35 & 10qter in 21% of normals
    - Deletions in 10qter DNA repeats do not cause disease
- New mutations often associated with somatic mosaicism for large deletion
  - Mosaic males: Typically sporadic patients with (mild) FSH phenotype
  - Mosaic females
    - More often clinically unaffected
    - May be parent of non-mosaic de novo patient
  - Degree of somatic mosaicism
    - Correlates with severity & age at onset of FSH
    - Mosaic females higher degree than Mosaic males
    - Mosaic mutations often detectable in blood
- Predisposition to somatic mutations
  
  10qter LOCUS with translocated 4q35 units
  Common in individuals with
  FSH somatic mosaicism
  - 4q35-type repeat arrays translocated to chromosome 10qter
    - 10% of chromosomes from normals
    - 50% of chromosomes in individuals with FSH somatic mosaicism
  - ? 4q35 Translocations to 10qter predispose to
    - Development of somatic mosaicism for 4q35 deletion
    - De novo appearance of FSH in individual or child
- Postulated mechanism for predisposition to deletion at 4q35
  - Increased homology between chromosomes 10 & 4
    - Produced by extra 4q35 repeats on chromosome 10qter
  - Homology leads to recombination of 4q35 & 10qter DNA
  - Recombination produces reduction of 3.3k Kpnl DNA units
  - Reduction of DNA units below 9 produces disease
FSH: Postulated mechanism(s) by which deletion in D4Z4 repeat sequence causes disease
- Hypomethylation of 4q D4Z4 repeat block
  - Aberrant interaction of FSHD region chromatin with nuclear envelope
  - DUX4 expression & toxic effect
    - Open reading frame in tandem repeat has changed expression due to disease deletion
    - DUX4 gene is transcribed only, or is increased, with shorter or hypomethylated repeat sequences
- Transcriptional misregulation of neighboring genes ⁸
  - FRG1 protein
    - Localized in nucleoplasm: Most prominently in nucleoli, Cajal bodies & speckles
    - Present in protein complexes containing human spliceosomes : Involved in RNA biogenesis
    - Binding partners: SMN, PABPN1 & FAM71B (speckle & Cajal body protein) ²³
    - Over-expression
      - Causes myopathy in mouse ¹⁸
      - Produces altered splicing of muscle mRNA
  - Other proteins from neighboring genes
    - FRG2 & ANT1: Do not produce myopathy
    - DUX4c (DUX4L9) ⁵⁰
      - Suppresses expression of DUX4 target genes
      - Prevents β-Catenin nuclear accumulation induced by DUX4
  - Mechanism not confirmed
- Telomeric silencing
  - Normal length of repeats prevents neighboring genes from telomeric silencing
  - Short repeat length allows telomeric silencing of neighboring genes
Mutations (Deletions) in 4q35 DNA repeats producing no disease
- Tandem repeats completely absent
  - Complete deletion of tandem repeats
  - Monosomy of distal end of 4q
- Translocation of homologous chromosome 10qter DNA repeats to chromosome 4q35
- Tandem repeat deletion on chromosome with telomeric 4qB polymorphism

DUX4 protein ²⁵

Translation
- Only DUX4 gene in most distal D4Z4 element is likely to be translated
- Requires specific permissive haplotype distal to D4Z4 array
  - Contains polymorphism that creates a polyadenylation signal
Cellular Localization: Nuclei
- Homeobox transcription factor: Homebox domains confer nuclear targeting
- Actively transported through nuclear pore complex
- FSH: Variably expressed among nuclei
Tissue localization
- Luminal cells of testis: Likely spermatogonia & Primary spermatocytes
- Low levels in thymus
- Silenced in most somatic tissues
  - Silencing mechanism: Repeat-mediated epigenetic repression
DUX4 expression
- Myoblasts
  - Normal
    - Low levels
    - No adenylation
  - FSH dystrophy
    - Upregulated
    - Polyadenylated
- SMCHD1: Binds directly to DUX4
DUX4 Actions
- Pro-apoptotic
  - Induces: Caspase 3/7 activity
  - Alters: Emerin distribution at nuclear envelope
- Germline transcription factor
  - Induces factors that create inflammatory reaction in muscle
  - FAT1: 1 target molecule
- Represses MyoD & its target genes ²⁷
  - Diminished myogenic differentiation
  - Repression of glutathione redox pathway components
  - Sensitivity to oxidative stress
  - Competes with Pax3/Pax7: Pax3 or Pax7 expression at high levels reduces DUX4 toxicity
  - ? DUX4 expression interferes with Pax7 in satellite cells
    - Inappropriately regulates Pax targets during regeneration
- Transiently expressed in four-cell human embryos
  - Activates cleavage-stage transcriptional program
  - May regulate: Zygotic genome activation (ZGA)
Other associations: Club foot
- Interacts with 30-bp sequence in PITX1 promoter: Transcriptional activator

FSH: Clinical-Genetic correlations

Inheritance
- Dominant: 70% to 90%
- Sporadic mutation
  - FSHD1: 10% to 30%
    - May be related to somatic mosaicism in asymptomatic parent
      - Especially mother
    - ? Predisposition when 4q35 repeat DNA translocated to chromosome 10
  - FSHD2: 67%
- FSH-like families not linked to 4q35: ~5%
Size of Chromosome 4q35 deletion: Related to Disease severity
- Largest deletions
  - D4Z4 repeat size: Smallest remaining fragment
  - Disease features
    - Congenital onset FSH
    - CNS changes
  - Parents usually minimally (mother) or not affected
  - Mother may be somatic mosaic
    - Fragment sizes: Normal size & Very small
- Large deletion
  - D4Z4 repeat size: 2 or 3 repeats; 10 to 13 kB DNA fragment
  - Usually results from new mutation
  - Disease features
    - Early onset (1 to 16 yrs)
    - Severe weakness
    - Hearing loss in childhood: More common
- Intermediate deletion
  - D4Z4 repeat size: 4 to 7; > 16 kB DNA fragment
  - Disease features
    - Onset: 8 to 22 yrs
    - Large typical families
    - Some non-penetrance ¹³
- Small deletion
  - D4Z4 repeat size: 8 to 10; > 35 kB DNA fragment
  - Small families; Later onset (Median 15 to 23 yrs)
  - Some non-penetrance @ 20 yrs
  - Syndromes: Clinical or Subclinical
    - Abdominal weakness; CK high
    - Scapuloperoneal weakness
      - Scapular winging
      - Foot dorsiflexion weakness
      - Also see scapuloperoneal syndromes
    - More severe disease than expected for repeat size
      - Some patients have additional SMCHD1 mutation
- Indeterminate fragment size: 35 to 48 kb
  - Sub-clinical syndromes may occur
- Normal fragment: 48 kb to 300 kb in healthy individuals
D4Z4 hypomethylation
- No relation to severity in FSHD1
- Possible relation to severity in FSHD2
Homozygote for deletion: 1 patient described ¹³
- Not necessarily more affected than heterozygotes in family
FSHD2 severity: No relation to D4Z4 repeat size

FSH (4q35) LOCUS
Congenital FSH
1 D4Z4 repeat

FSH (4q35) LOCUS
Typical FSH
Few D4Z4 repeats

FSH (4q35) LOCUS
Mild or atypical FSH
Mildly reduced number
of D4Z4 repeats

NORMAL FSH LOCUS AT 4q35
Number of D4Z4 DNA repeats: Normal
D4Z4 methylation: High
Chromatin: Closed
4q region distal to repeats: Variable
Distal DUX4 gene: Not expressed

FSH: Clinical features

FSHD1 vs; FSHD2 ³³
- Clinical features: Same
- Symptom onset: Possibly later in FSHD2
Disease onset
- Age: Congenital to Late age; Mean 3rd decade
- Penetrance
  - Exam: 90% to 95% of patients with weakness by age 20
  - High with 1 to 3 remaining repeats (Large deletion)
  - Symptoms: 1/3 of patients asymptomatic (More with smaller deletion)
- Weakness: Symptoms & Signs ¹⁰
  - Usual (72%-85%): Face & Scapular; Often asymmetric (40%)
  - Face predominant (7%): Usually have scapulo-humeral involvement on exam
  - Face sparing (5%-15%): Usually later onset (4th or 5th decade); Smaller deletion
  - Foot drop (13%): May be unilateral; Face & Scapulo-humeral weakness on exam
  - Proximal leg (7%): More common in females; Bilateral; Older onset; Larger deletion
  - Other: Distal posterior leg (1%); Bent spine
- Infantile onset
  - Frequency: 2% to 5% of FSH
  - Associated with severe general & facial weakness
  - Other systems often involved: Hearing loss; Visual loss (Coat's); ? Epilepsy
Weakness
- Symptomatic in 80% of family members
- Asymmetric
- Face
  - Initial manifestation: Often
  - Frequency: 95% at age 30 with examination
  - Asymmetry: Some patients
    - Especially orbicularis oris
    - Clinical test
      - Opposition of lips
      - Ask patient to pucker lips
  - Functional changes
    - Eyes: Often early in disease course
      - Lid closure: Incomplete
      - Sleeping: With eyes open
    - Bulbar dysfunction
      - Using straws
      - Blowing up balloons
    - Speech: Dysarthria
      - Especially labial consonants
    - Mouth
      - Transverse smile
      - Pouting mouth (Bouche de tapir)
  - Some 4q35 linked patients have no facial weakness
- Upper extremity: Earliest disabling feature
  - Scapular: Latissimus dorsi; Trapezius; Rhomboids; Serratus anterior
  - Humeral: Especially biceps
  - Arm abduction: Weak 2° poor scapular fixation; Deltoids normal
  - Distal: Wrist extensors involved later in course
- Lower extremity
  - Peroneal
    - Ankle dorsiflexion weaker than toe dorsiflexion
    - Rare in absence of face weakness
  - Proximal muscles
    - Involved with disease progression
    - 50% of mutation carriers
- Trunk weakness
  - Pectoral (Clavicular head)
  - Lower abdominal
    - Beevor's sign: Cephalad displacement of umbilicus with upper truncal flexion
- Muscles usually spared: Bulbar, Extraocular, Deltoid & Respiratory
  - Tongue atrophy: With larger deletions
  - Respiratory support: Eventually needed in 1%
- Variant patterns
  - Hemiatrophy ³²
  - Bent spine: Axial myopathy ³⁰
Skeletal & morphologic
- Rest: Slope shouldered; anterior rotation of shoulders
- Scapular winging & Triangular shoulders
  - Worse with arm forward movement & abduction
- Pectus excavatum
- Reversal (Upward slope) of axillary folds
Progression
- Descending: Face → Arms → Legs
- Slow: ? Step-wise in some periods
- Linear between 20 to 50 years
- ? Strength stabilizes in later life
- Wheelchair confinement in 20%
- Prognosis: Worse with younger onset
- Pregnancy ²⁰
  - General outcome: Good
  - Child: Higher rates of low birth weight & total operative deliveries
  - Mother
    - Worsening in 24% of gestations
    - No resolution after delivery
- Life expectancy: Often normal
Intergenerational features
- Anticipation: Probably none
  - Reported in some families
    - ? Relation to reduced severity in females
  - No changes in deletion size
- Parental sex
  - Asymptomatic mothers
    - More affected sons than daughters
  - Severe disease: More commonly 2° to
    - New mutations, or
    - Mutations transmitted through maternal lines
- New mutations: ~ 1/3 of cases
  - No effect on severity in offspring
  - Reduced male reproductive fitness
  - New mutations more frequent in females
  - May occur initially as: Somatic mosaicism in parent; de novo mutation
Other systems
- General
  - More common with larger 4q35 deletions: 1 to 3 remaining D4Z4 repeats
- Sensorineural hearing loss
  - High frequency: 75%
  - Progressive
  - Often not symptomatic
  - May be present in severe infantile cases
- Coats' disease: Vasculopathy
  - Retinal telangectasia & detachment
  - Frequency of retinal disease: 60% in mroe severe FSH
  - Often not symptomatic
  - Blindness < 1%
- Cardiovascular
  - Labile hypertension
  - Arrhythmia or Conduction block (2% to 5%) ⁶: ? Mild increased incidence
- CNS: With largest deletions (EcoRI fragment size 10 or 11 kb)
  - Mental retardation (89%)
  - Epilepsy (40%)
  - Japanese patients
- Neoplasm
  - FSHD1 > 40 years of age: May have ↑ risk of GI neoplasm ⁵²
Variant syndrome: Severe infantile FSH dystrophy ⁴¹
- Frequency: 2% to 4% of all FSH
- Genetics
  - D4Z4 repeat (EcoRI fragment) sizes
    - Usually very short fragment: Especially with onset ≤ 1 year
    - Range: 9 to 21 kB
    - Shortest EcoRI fragment: Most severe syndromes
  - Inheritance: Several patterns
    - de novo mutation
    - Inheritance from a parent with
      - Somatic mosaicism
      - Classical or mild adult clinical FSHD but large D4Z4 deletion
- Early feature
  - Onset: Infancy to 5 years
  - Facial weakness
    - Onset < 5 years
    - Weak eye closure: Apparent during sleep
    - Inability to smile
  - Motor milestones: Normal
- Clinical
  - Weakness
    - Onset < 10 years
    - Pelvic often ≥ Shoulder
    - Foot drop (60%)
    - Degree: Severe
    - Asymmetric (70%)
    - Respiratory (50%): Failure in 10%
    - Dysphagia (20%)
    - Course: May be rapid progression in legs to loss of ambulation
  - Muscle pain: Legs
  - Course
    - Rapid progression
    - Wheelchair: 10 years after onset of weakness
  - Muscle wasting: Marked
  - Skeletal: Hyperlordosis; Kyphoscoliosis
  - Other systems often involved
    - Hearing loss (90%): Sensorineural; Bilateral
    - Visual loss (100%)
      - Coat's
      - Tortuous retinal vessels
    - CNS (30%)
      - Epilepsy (20%)
      - Mental retardation (30%): Moderate to severe; Smallest EcoRI fragments
  - Cardiac arrhythmias (50%): AV block; Echocardiography normal
- Laboratory
  - Serum CK: 70 to 1,400
  - Muscle biopsy
    - Muscle fiber size: Varied; Type 2 hypertrophy; Small angular
    - Inflammatory cells: Perivascular & Endomysial
FSH variant: Bent spine syndrome ³⁰
- Epidemiology: 1 family
- Mutation: 4q35 repeat contraction
- Clinical
  - Onset: 6th to 7th decade
  - Bent spine
  - Strength: Arm & Leg normal
- Laboratory
  - MRI: Paraspinous muscle atrophy
  - Serum CK: Normal
- Differential diagnosis

Duchenne

Landouzy-Dejerine Syndrome

Chaddock 1900

Scapular winging

Putnam

FSH: Laboratory features
- CK: Normal (25%) to < 5-fold elevated
- EMG: Myopathic
- Muscle biopsy
  - Fiber size: Varied
    - Small fibers: Rounded & Angular
    - Hypertrophic muscle fibers especially common
      - Often with few internal nuclei
      - Internal architecture relatively normal
      - More commonly type 2
  - Necrotic muscle fibers: Occasional
  - Inflammation (75%)
    - Location: Endomysial; Perivascular
    - Cells: Perivascular CD4+; Endomysial CD8+
  - MHC Class I upregulation by muscle fibers: Common
  - Muscle to biopsy (Rarely necessary): Biceps or Suprascapular; Deltoid often spared
- MRI ⁴²
  - Most frequent: Trunk
    - Muscles: Back extensors (Thoracic), Abdominal, Trapezius (97%),
      Latissimus dorsi (94%), Pectoralis, Rhomboid; Serratus anterior
  - Asymmetry: 45% of muscles
  - Right > Left
  - Thigh: Image; Semi-membranosus & Semitendinosus
  - Leg: Anterior tibial
  - Severity: Weak relation to D4Z4 repeat length
  - Unusual: Psoas; Neck, Posterior & Anterior; Spinati; Subscapularis
  - Types of changes: Fat infiltration; Hyperintensity on short-tau inversion recovery (STIR)
FSH: Treatment
- Albuterol treatment produces
  - Increased muscle mass
  - No significant change in strength
- OT & PT: Aids in ADLs
- Experimental trial: Losmapimod
FSH: Differential diagnosis
- FSH 1B
- PROMM
- HIBM + Paget's disease
- Emery-Dreifuss
- Scapuloperoneal syndromes
- Becker MD ¹⁴
- Mitochondrial myopathy
- Myasthenia gravis, AChR Ab+ ⁵⁶
  - May ocur in FSHD patients > 45 years with 7 to 10 repeat units

FSH mechanisms

General mechanism
- D4Z4 repeats in mutated region control expression of neighboring genes via a protein complex (DRC)
- FSH deletion produces altered expression of neighboring genes
D4Z4 action
- Active region of D4Z4
  - 27 base pair element (DBE) of D4Z4
  - Binds regulatory protein complex (DRC) via transcriptoin factor YY1
  - Action: Transcriptional repression of neighboring genes
- Components of DRC regulatory protein complex
  - YY1 : Transcriptional repressor; Binds to DBE on D4Z4
  - HMGB2 : Nonhistone chromatin-associated protein; Architectural protein
  - Nucleolin : Component of transcription factor complexes; Interacts with other nuclear components
- Function & action of DRC protein complex
  - Inhibits expression of neighboring genes
  - Reduced levels of elements of complex: Produces over-expression of neighboring 4q35 genes
Transcriptional misregulation of neighboring genes ⁸: Candidate regulated neighboring genes
- frg2: Not expressed in normal muscle; Expressed in FSH muscle
- frg1: Over-expressed in FSH muscle
- ANT1
  - Over-expressed in FSH muscle
  - Mutations produce PEO
  - Over-expression may induce apoptosis
Expression changes in 4q35 neighboring genes are associated with
- Distance from D4Z4
  - Normal muscle: Expression level of 4q35 genes increases with distance from D4Z4
  - FSH muscle: Level of overexpression varies inversely with distance from D4Z4
- Size of D4Z4 repeat sequence
  - FRG2 overexpression is inversely related to number of D4Z4 repeats
- Tissue: Over-expression in FSH is muscle specific
D4Z4 deletion effects
- Reduce ability of regulatory proteins to bind to D4Z4 repeat
- Allow increased expression of neighboring genes
- Increased expression of 1 or several neighboring genes leads to FSH myopathy by unknown mechanism
- D4Z4 hypomethylation¹²
  - Also occurs in FSH phenotype without D4Z4 deletion
  - May be common factor producing FSH phenotype

SCAPULOPERONEAL SYNDROMES: Without 4q35 linkage, ± Facial weakness

ACTA1: 1q42; Dominant
Centronuclear myopathy (Adult-onset): MYF6; 12q21; Dominant
Davidenkow's syndrome
Emery-Dreifuss Dystrophies
FSHD with ragged red fibers & cardiomyopathy
Glycogen storage
Acid maltase deficiency with scapuloperoneal weakness
Phosphorylase deficiency (McArdles)
Kaeser: Desmin; 2q35
LGMD2A: Calpain 3; 15q15
Mitochondrial
Myopathy + Paget's disease of bone
with Dementia: VCP; 9p13
Type 2
Reducing body myopathy (Adult onset): FHL1; Xq26
Retardation & Cardiomyopathy: LAMP-2; Xq24
Scapuloperoneal MD (SPMD) with Hyaline bodies
Type 1: FHL1; Xq26; Dominant
Type 2: MYH7; 14q12; Dominant
Type 3: MYH7; 14q12; Recessive
Myosin storage myopathy: MYH7; 14q12
Scapuloeroneal myopathy + CMG: Plec1; 8q24
Scapuloperoneal neuronopathy: TRPV4; 12q24

Also see: Absent muscles; Holt-Oram; FSH

Scapuloperoneal muscular dystrophy, Type 1 (Hyaline body myopathy)

● Four-and-a-half-LIM domains 1 (FHL1)

; Chromosome Xq26.3; Dominant ²⁶

Epidemiology: Italian, Austrian & English families
Genetics
- Mutation: Missense (Trp122Ser) & In-frame insertion
- Genetic-clinical correlations
  - Penetrance 60% to 80%; ? allele specific
  - Succeeding generations of same sex more affected
- Allelic syndromes
  - X-linked myopathy with postural muscle atrophy (XMPMA)
  - Reducing body myopathy
    - Severe, Early onset
    - Child or Adult onset
  - Rigid spine syndrome
  - Myofibrillar myopathy
  - Emery-Dreifuss 6
  - Scapuloperoneal muscular dystrophy, Type 1 (Hyaline body myopathy)
  - Uruguay syndrome
FHL-1 protein
- Highly expressed in skeletal & cardiac muscles
  - Localizes to sarcomere & sarcolemma
  - May participate in muscle growth and differentiation + Assembly of sarcomere
  - Interactions: Slow & Cardiac isoforms of myosin binding protein C (MyBP-C), ERK2, HPC2, RING1 & KBP1
- 3 major isoforms: Generated by alternative splicing
  - FHL1A (Skeletal muscle LIM protein 1 (SLIM1)): Full-length protein
  - FHL1B (SLIMMER): Contains LIM domains 1–3, nuclear localization & export signals & RBP-J binding region
  - FHL1C (KyoT2): Shortest isoform; Contains LIM domains 1 & 2 & RBP-J binding region; Interacts with PIAS1
- LIM domain: Double zinc finger motif
- Regulates functional expression of KCNA5
- Regulation of ultra-rapid activating delayed rectifier K⁺ current & atrial arrhythmia
- Patients: Levels of FHL1 protein decreased in milder & increased in more severe disease
  - Marked decrease in FHL-1 expression: XMPMA; Emery-Dreifuss
  - Slightly decreased: X-SM; RBM, late onset
  - Increased: RBM, early onset
- Other disease relations
  - Target of autoantibodies in immune myopathies
  - Chikungunya virus: Host factor ⁴⁹
Clinical
- Onset age: 20 to 58 years
- Weakness
  - Early: Legs; Foot drop
  - Arms: Proximal > Distal
  - Scapular winging
  - Postural muscles: Bent spine
  - Asymmetry
  - Variable Progression: Rapid or slow
- Muscle: Hypertrophy
- Other features in some patients
  - Skeletal: Contractures; Rigid spine
  - Hearing loss
  - Cardiac disorders
- Death: Cardiac or respiratory failure
Laboratory
- CK: High; 1.5 to 10 times normal
- MRI
Muscle pathology
- Focal myopathic changes
- Inclusions: Hyaline bodies
  - Eosinophilic on H&E
  - Location: Central or subsarcolemmal
  - Most often in type I fibers; Some in type II
  - Composition: Desmin, FHL1, & Dystrophin

FHL1 mutations: Common features
Scapular winging
Joint contractures
Rigid spine
Respiratory weakness
Cardiomyopathy
Reducing bodies
FHL1 levels: Reduced
Except: Reducing body myopathy

Variant FHL1 syndrome: Reducing body myopathy
Also see: Congenital hyaline body myopathy
Variant FHL1 syndrome: X-linked myopathy with postural muscle atrophy (XMPMA)
- Mutations: C terminal of FHL1 gene
- Onset age: 15 to 75 years
- Clinical
  - Milder disease than other FHL1 mutations
  - Postural muscle atrophy
  - Respiratory failure
  - Rigid spine
  - Muscle hypertrophy
  - Ankle: Tendon contracture
- Laboratory
  - Serum CK: High; Range Normal to 10x elevated
  - EMG: Myopathy + Spontaneous activity
  - Muscle
    - Type 2A: Hypertrophy
    - Type 2B: Atrophy
    - Desmin: Stains aggregates in muscle fibers
Variant FHL1 syndrome: Emery-Dreifuss Muscular Dystrophy 6 ²⁸
- Genetics
  - Inheritance: Recessive or Semi-Dominant; 1 Sporadic patient
  - Mutations
    - 14 identified
    - Types: Missense (Cys209Arg, Cys276Tyr); Loss of termination codon (X281Glu); Out-of-frame insertions or deletions
- FHL1 protein: Mutation effects
  - Residual FHL1 protein present
    - Severe phenotype
    - Severe delay in myotube formation
  - Absent protein
    - Milder phenotype
    - Less weakness
- Clinical
  - Onset age: 4 to 48 years; Mean = 15
  - Myopathy
    - Distribution: Scapulo-Peroneal and/or Axial
      - Legs (100%): Pelvic, Peroneal or Pelvi-peroneal
      - Arms (85%): Scapular
      - Axial (55%)
      - Face (28%)
      - Respiratory
    - Hypertrophy (28%)
    - Ptosis (14%)
  - Dysphonia (45%): Abnormal vocal cords
  - Cardiac disease: Only feature in some patients
    - Arrhythmias: Supraventricular or Ventricular
    - Hypertrophic cardiomyopathy
    - Conduction defects
  - Joint contractures
    - Neck stiffness
    - Rigid spine
    - Limb-joint: Ankles (100%), Elbows; Knees, Hips, Wrists (one patient), Fingers, Shoulders
    - Scoliosis
  - Course
    - Progressive
    - Patients usually remain ambulant
- Laboratory
  - Serum CK: Normal to 6x elevated
  - Muscle pathology
    - Fiber size variation
    - Endomysial connective tissue increased
    - Rimmed vacuoles: Some muscles
    - Muscle fiber internal architecture: Irregular
    - FHL1: Reduced or Absent; Remaining protein near nucleus
    - No reducing bodies (Menadione-NBT) or aggregates (myotilin, desmin or αB-crystallin)
    - Normal: Lamin A & C; Emerin
  - Muscle MRI involvement: Erector spinae; Posterior thigh; Anterior & Lateral leg
- Female heterozygote carriers
  - Asymptomatic, or
  - Cardiac disease and/or Myopathy, mild

Scapuloperoneal muscular dystrophy, Adult onset, Type 2 (Hyaline body myopathy; SPMM) ³
● MYH7 ; Chromosome 14q11.2; Dominant
- Genetics
  - Mutation: Arg1845Trp
  - Allelic disorders
- Clinical
  - Onset: 1st to 5th decade
  - Weakness: Scapuloperoneal
    - Neck flexion
    - Shoulder abduction
    - Knee flexion
    - Ankle dorsiflexion
  - Progression: Slow
- Laboratory
  - Serum CK: Mildly elevated
  - Muscle pathology
    - Variable fiber size
    - Hyaline bodies
      - Only in type I fibers
      - Subsarcolemmal
      - Stain for: Myosin heavy chain, Slow; ATPase, acid pH (4.3)
Scapuloperoneal muscular dystrophy, Type 3 (Hyaline body myopathy; Myosin storage, MSMB; CMYP7B) ¹¹
● Myosin - Cardiac β heavy chain (MYH7) ; Chromosome 14q11.2; Recessive
- Epidemiology: Turkish family; 2 siblings
- Genetics
  - Mutation: Arg1820Trp; Homozygous
  - Allelic disorders
- MYH7 protein
- Clinical
  - Onset: 1st to 4th decade
  - Weakness: Scapuloperoneal
    - Neck flexion
    - Shoulder girdle
    - Ankle dorsiflexion
  - Tendon reflexes: Normal
  - Systemic: 1 patient with cardiomyopathy
  - Progression: Slow
- Laboratory
  - Serum CK: 2x to 3x normal
  - Muscle pathology
    - Type I muscle fiber predominance
    - Central nuclei
    - Variable muscle fiber size
    - Muscle fiber splitting
    - Hyaline bodies
      - Only in type I fibers
      - Subsarcolemmal
      - Stain for: ATPase, acid pH (4.3)
Scapuloperoneal muscular dystrophy with mental retardation & lethal cardiomyopathy
● LAMP-2 ; Xq24; Recessive or Semi-Dominant
- Genetics
  - Allelic disorder: Danon disease
- Clinical
  - Course
    - Onset: 5 to 25 years
    - Death: 2nd or 3rd decade
  - Weakness: Humeroperoneal; Distal
  - CNS: Mental retardation
  - Systemic
    - Cardiomyopathy: Hypertrophic
    - Myopia
- Laboratory
  - Serum CK: High
  - Muscle biopsy
    - Variable muscle fiber size
    - Vacuoles: Cytoplasmic; Small; Basophilic; Dystrophin +
- Mother (carrier) with cardiomyopathy
Kaeser Scapuloperoneal syndrome (SCPNK) ²⁴
● Desmin ; Chromosome 2q35; Dominant
- Epidemiology
  - 1 family: Originally reported as neuropathic
  - Same mutation found in other German families
- Genetics: Missense mutation; R350P
- Desmin protein: See Desmin myopathies
- Clinical
  - Onset
    - Age: 3rd to 4th decade
    - Later for females
  - Weakness
    - Scapuloperoneal
    - Foot drop
    - Bulbar: Late; Dysphagia
    - Face
    - Spared: Biceps
  - Myalgias: Some patients
  - Gynecomastia
  - Course
    - Progressive
    - More sudden death & respiratory failure in males
- Laboratory
  - Electrophysiology
    - EMG: Myopathic; Mildly neurogenic
  - Serum CK: High
  - Muscle pathology: Normal to Myofibrillar myopathy
Scapuloperoneal peripheral neuropathy (Davidenkow's Syndrome)
● Autosomal Dominant
- Genetics
  - Some patients reported with HNPP mutations (PMP-22 deletions) ²¹
- Clinical
  - Onset age: Childhood or adult
  - Weakness
    - Distal legs: Early
    - Shoulder girdle
  - Tendon reflexes
    - Generally decreased
    - Absent at ankles
- Laboratory
  - CK: Normal
  - Electrodiagnostic: Axonal neuropathy; Absent sensory potentials
Scapuloperoneal neuropathy (SPSMA)
● TRPV4 ; Chromosome 12q24.11; Dominant
- Epidemiology
  - New England, French-Canadian family
  - Males more severely affected than females
  - Disease more severe in succeeding generations
- Genetics
  - Mutations: Arg269Cys; Arg315Trp; Arg316Cys
  - Allelic disorders
- TRPV4 protein
- Clinical
  - Onset ages: Congenital to Adult
  - Congenital absence of muscles
  - Weakness
    - Course: Progressive
    - Distribution
      - Scapuloperoneal
        
        Scapular winging
      - Distal
      - Laryngeal palsy
      - Diaphragm
    - Tendon reflexes: Reduced
- Pathology
  - Muscle: Chronic denervation
    - Grouped atrophy
    - Fiber type grouping
    - Internal nuclei
    - Pyknotic nuclear clumps
    - Vacuoles & Aggregates
  - Motor neurons
    - Normal numbers in Spinal cord & Brain
● Autosomal Dominant
- Weakness: Face & Pectoral muscles
- Onset: Early adult
- Electrophysiology: SMA, FSH type
● Autosomal Recessive
Other Scapuloperoneal syndromes
- Emery-Dreifuss Dystrophy
- Acid maltase deficiency with scapuloperoneal weakness
- Centronuclear myopathy: Adult-onset; Dominant
- FSH phenotype with ragged red fibers & cardiomyopathy

Other myopathies

Facioscapulohumeral muscular dystrophy gene testing

University of Iowa Hospitals & Clinics
200 Hawkins Drive
Microbiology Laboratory
BT 6004 GH
Iowa City, Iowa 52242-1009
319-356-2591
Fax: 319-384-9854

10 ml Lavender top (EDTA) tube

Return to Limb-Girdle dystrophies
Return to Myopathy & NMJ Index

References
1. Neurology 2000;54:1218-1221
2. Science 2000;289:1769-1772, Hum Mol Genet 2004;13:3079-88
3. Neurology 1997;48:253-257
4. EMBO Journal 2000;19:4439-4448, Hum Molec Genet 2002;11:805-814
5. Neurology 2001;56:794-796, Neurology 2002;59:1876–1880
6. Neuromuscular Disorders 2001;11:616-617
7. Neuromuscular Disorders 2001;11:525-529
8. Cell 2002;110:339-348
9. Nat Genet 2002;32:235-6
10. Neuromuscular Disorders 2002;12:874-877, Clin Neurol Neurosurg 2011 Nov 11
11. Neuromuscul Disord 2004;14:4-9
12. Nature Genet 2003; Online November 2002
13. J Med Genet 2004;41:e17
14. J Neurol Sci 2004;219:89-93
15. Neurology 2004;62:1081-1089
16. Brain 2004;127:1979-92
17. Hum Mol Genet 2004;13:1857-71
18. Nature 2005; Online Dec 11
19. J Neurol 2006; Online March
20. Neurology 2006;67:1887–1889
21. Muscle Nerve 2005;32:668-671, Muscle Nerve 2018;57:E108-E110
22. Neurology 2007 Jan 17
23. Chromosoma 2007;116:53-64
24. Brain 2007 Apr 17
25. Neuromuscular Disorders 2007;17:611–623, Neuromuscul Disord 2008 Oct 28
26. Am J Hum Genet 2008;82:208-213; Am J Hum Genet 2008;82:88-99
27. EMBO J 2008;27:2766-2779
28. Am J Hum Genet 2009; Online August, Hum Mutat 2022;43:1234-1238
29. Hum Mutat 2009;30:1449-1459
30. Muscle Nerve 2010;42:273-275
31. Science 2010; Online Aug 19
32. Neurology 2009;73:e24
33. Neurology 2010;75:1548–1554
34. Neuromuscular Disorders 2011; Online November
35. Brain 2011; Online November
36. Hum Mol Genet 2011 Dec 2
37. Neuromuscul Disord 2011 Dec 1
38. J Biol Chem 2011;286:40296-40306
39. JAMA 2012;1292-1301
40. Nature Genet 2012; Online November
41. Neuromuscul Disord 2013 Feb 20
42. Neuromuscul Disord 2014 June, PLoS One 2014 Jun 16;9(6):e100292
43. Muscle & Nerve 2016; Online April, Neurology 2024;103:e209883
44. Am J Hum Genet 2016;98:1020-1029
45. Brain 2018 Aug
46. Hum Mol Genet 2018;27:3488-3497
47. Neurology 2019 Apr 12
48. Neurology 2020 May 28
49. C R Biol 2021;343:79-89
50. Front Cell Dev Biol 2022;10:802573
51. J Neuropathol Exp Neurol 2022;82:29-37
52. J Hum Genet 2023;68:91-95
53. J Clin Med 2025;14:8197
54. Continuum (Minneap Minn) 2025;31:1329-1343
55. Skelet Muscle 2025;15:24
56. Eur J Neurol 2026;33:e70477

1/17/2026